Results 41 to 50 of about 2,856,278 (190)

Danazol-induced Stevens-Johnson syndrome in a patient with systemic lupus erythematosus [PDF]

open access: yes, 2015
A patient with Stevens-Johnson syndrome related to danazol is ...
Koh, MJA   +6 more
core   +1 more source

Updated COVID‐19 Vaccines and Health Outcomes in Patients With Autoimmune Rheumatic Conditions

open access: yesArthritis &Rheumatology, EarlyView.
Objective We aimed to assess the association between COVID‐19 vaccination status and COVID‐19‐related hospital admissions, need for mechanical ventilation or extracorporeal membrane oxygenation (ECMO), and death in people with autoimmune rheumatic conditions. Methods We conducted a retrospective cohort study using National Clinical Cohort Collaborative
Lesley E. Jackson   +127 more
wiley   +1 more source

Stevens-Johnson Syndrome associated with brucella infection

open access: yes, 2007
Stevens-Johnson syndrome is a potentially fatal condition that manifests mainly on the skin and mucosal surfaces but also affects other vital organs. There are no report of Stevens-Johnson syndrome caused by brucella infection in the literature.
Kumral, ABDULLAH   +15 more
core   +1 more source

HLA‐B*15:21 carrier status is a susceptibility factor of carbamazepine‐induced nonimmediate cutaneous adverse reactions in HLA‐B*15:02‐negative patients: A retrospective cohort study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
After HLA‐B*15:02 screening, the residual risk of carbamazepine‐induced nonimmediate cutaneous adverse reactions is 0.059. Among these HLA‐B*15:02‐negative cases, HLA‐B*15:11 and HLA‐B*15:21 carrier status significantly increases the risk of carbamazepine‐induced nonimmediate cADR.
Warit Ruanglertboon   +11 more
wiley   +1 more source

Safety outcomes of antidiabetic medications: A comprehensive review of the EU summaries of product characteristics and international clinical practice guidelines

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Information on the safety profile of antidiabetic medications is essential for informed treatment decisions in type 2 diabetes mellitus. Although this information is available in regulatory documents of individual drugs, a comprehensive overview across all approved antidiabetics is lacking.
David Liang   +5 more
wiley   +1 more source

Successful Treatment of a Paroxysmal Kinesigenic Dyskinesia Patient with Carbamazepine-Induced Stevens-Johnson Syndrome Using Oxcarbazepine Monotherapy: A Case Report

open access: yesCase Reports in Neurology, 2021
Paroxysmal kinesigenic dyskinesia (PKD) is a rare condition characterized by abnormal involuntary movements that are precipitated by a sudden movement. PKD is often misdiagnosed with psychogenic movement disorders.
Hung T. Tran   +2 more
doaj   +1 more source

Causality assessment tool for drug‐induced acute kidney injury in patients admitted to intensive care units: Requirements from a multicentre retrospective study in the Netherlands reusing data from electronic health records

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim This study aimed to provide key requirements for a drug‐induced acute kidney injury (d‐AKI) causality assessment tool (CAT) for intensive care unit (ICU) patients, using vancomycin‐induced AKI (v‐AKI) as a test case. Methods A retrospective review was conducted by medical experts of electronic health records of ICU patients from 14 Dutch ICUs.
Joanna E. Klopotowska   +44 more
wiley   +1 more source

Stevens-Johnson Syndrome

open access: yes, 1984
The clinical manifestations, including variations, of the Stevens-Johnson syndrome (SJS) are reviewed. Lesions of the skin, eye, and mucous membranes are described and discussed.
Flowers, Franklin P.   +3 more
core   +1 more source

Mycoplasma-pneumonia-induced Stevens–Johnson syndrome in an adult: a case report

open access: yesJournal of Medical Case Reports
Background Stevens–Johnson syndrome epitomizes an acute, exceptionally rare, and capricious immunological phenomenon marked by potentially life-threatening skin reactions, involvement of mucous membranes, and concomitant systemic manifestations.
Fathima Thesleem Yoosuf   +6 more
doaj   +1 more source

Safety of proton pump inhibitors in children: A systematic review

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim To systematically evaluate the safety of proton pump inhibitor (PPI) therapy in children aged 0–12 years, with a focus on treatment‐emergent adverse events across different study designs and age groups. Method The systematic review was carried out according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA ...
Ahmad Raza Sachel   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy